Multivalent HIV Vaccine Induces Early and Potent Antibody Response Multivalent HIV Vaccine Induces Early and Potent Antibody Response

A multivalent HIV vaccine that consists of envelope protein (gp120 Env) and either DNA or NYVAC vectors during priming leads to early and potent IgG-binding antibody responses, according to results from the HIV Vaccine Trials Network (HVTN).Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: HIV/AIDS News Source Type: news

Related Links:

Vaccine knowledge and anticipated rates of vaccination even lower for pneumococcal disease
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Cardiology, Endocrinology, Family Medicine, Geriatrics, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Critical Care, Emergency Medicine, Nursing, Oncology, Pathology, Pediatrics, Pharmacy, Pulmonology, Rheumatology, Institutional, Source Type: news
This report summarizes a consultation meeting convened by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), on 12 September 2017 to discuss the scientific rationale for selectively testing relevant HIV vaccine candidates in early life that are designed to initiate immune responses for lifelong protective immunity. The urgent need to develop interventions providing durable protective immunity to HIV before sexual debut coupled with the practicality of infant vaccine schedules supports optimizing infant HIV vaccines as a high priority. The panelists discussed the unique o...
Source: Topics in HIV Medicine - Category: Infectious Diseases Authors: Tags: mSphere Source Type: research
Thanks to a $129 million federal grant, the Duke Human Vaccine Institute (DHVI) will continue its now 14-year long effort to develop a vaccine for HIV. The National Institute of Allergy and Infectious Disease has announced a seven-year grant totaling at least $129 million to the DHVI. Under the terms of the grant, the institute could also award an additional $18 million – potentially bringing funding to $147 million.  The grants fund the Duke Consortia for HIV/AIDS Vaccine Development (CHAVD)…
Source: Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Statement by Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases, and Maureen M. Goodenow, Ph.D., NIH Associate Director for AIDS Research and Director, Office of AIDS Research
Source: National Institutes of Health (NIH) News Releases - Category: American Health Source Type: news
This report indicates that previous vaccination for hepatitis A did not reliably provide protection among some persons with HIV infection.Morbidity &Mortality Weekly Report
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: HIV/AIDS Journal Article Source Type: news
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study suggests that the antibiotic-induced changes in gut microbiota might contribute to the inflammation responses through the alternation of metabolic status, providing a novel insight regarding a complex network that integrates the different interactions between gut microbiota, metabolic functions, and immune responses in host. Introduction The gut microbiome plays an essential role in health and disease of the host. It is well-documented that gut microbiome aids the host in modulating immune responses and protecting against pathogens (Holmes et al., 2011). It also provides beneficial biological functions via...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
Lin Lei1, Karen Tran2, Yimeng Wang1, James J. Steinhardt1, Yongli Xiao3, Chi-I Chiang1, Richard T. Wyatt2,4 and Yuxing Li1,5* 1Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, United States 2IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, United States 3Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States 4Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States 5Department of Microbiology and Immu...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Jeffrey G. Shaffer1*, Frances J. Mather1, Mamadou Wele2, Jian Li1, Cheick Oumar Tangara2, Yaya Kassogue2, Sudesh K. Srivastav1, Oumar Thiero2, Mahamadou Diakite2, Modibo Sangare2, Djeneba Dabitao2, Mahamoudou Toure2, Abdoulaye A. Djimde2, Sekou Traore2, Brehima Diakite2, Mamadou B. Coulibaly2, Yaozhong Liu1, Michelle Lacey3, John J. Lefante1, Ousmane Koita2, John S. Schieffelin4, Donald J. Krogstad1 and Seydou O. Doumbia2 1Department of Global Biostatistics and Data Science, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, United States 2Faculty of Medicine and Odontostomatology, Un...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
This study was carried out after written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Stanford University and UCLA Institutional Review Boards. Author Contributions MB provided patient care and obtained IRB approval. RO prepared histology images. MB, TT, and RB designed the research. TT and LP conducted experiments and analyzed data. MB made the molecular model. MB and TT wrote the manuscript. Funding Funding for this work came from the Jeffrey Modell Foundation and from the NIH/NIGMS (R01 GM110482 to MB)....
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: AIDS Vaccine | Allergy | Allergy & Immunology | HIV AIDS | Vaccines